Patents by Inventor Denis Carniato

Denis Carniato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10851054
    Abstract: The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: December 1, 2020
    Assignees: BIOKINESIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Cecile Bougeret, Catherine Guillou, Julien Rouleau, Julie Rivollier, Denis Carniato
  • Publication number: 20190169124
    Abstract: The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
    Type: Application
    Filed: January 25, 2019
    Publication date: June 6, 2019
    Inventors: CECILE BOUGERET, CATHERINE GUILLOU, JULIEN ROULEAU, JULIE RIVOLLIER, DENIS CARNIATO
  • Patent number: 10308683
    Abstract: The invention relates to a new bicyclic lipolantipeptide, representing a new class of lantipeptide, and salts thereof, their preparation from a culture of a Microbacterium arborescens, and their use as antimicrobial agent in the prevention and treatment of infections in humans, animals or plants.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: June 4, 2019
    Assignee: DEINOVE
    Inventors: Josef Aszodi, Denis Carniato, Dominique Le Beller, Guillaume Lesquame, Marie-Helene Quernin
  • Patent number: 10189782
    Abstract: The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: January 29, 2019
    Assignees: BIOKINESIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Cecile Bougeret, Catherine Guillou, Julien Rouleau, Julie Rivollier, Denis Carniato
  • Publication number: 20180201646
    Abstract: The invention relates to a new bicyclic lipolantipeptide, representing a new class of lantipeptide, and salts thereof, their preparation from a culture of a Microbacterium arborescens, and their use as antimicrobial agent in the prevention and treatment of infections in humans, animals or plants.
    Type: Application
    Filed: July 1, 2016
    Publication date: July 19, 2018
    Inventors: JOSEF ASZODI, DENIS CARNIATO, DOMINIQUE LE BELLER, GUILLAUME LESQUAME, MARIE-HELENE QUERNIN
  • Publication number: 20170233342
    Abstract: The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
    Type: Application
    Filed: May 4, 2017
    Publication date: August 17, 2017
    Inventors: CECILE BOUGERET, CATHERINE GUILLOU, JULIEN ROULEAU, JULIE RIVOLLIER, DENIS CARNIATO
  • Patent number: 9643923
    Abstract: The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: May 9, 2017
    Assignees: BIOKINESIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Cécile Bougeret, Catherine Guillou, Julien Rouleau, Julie Rivollier, Denis Carniato
  • Publication number: 20160237042
    Abstract: Piperazinyl derivatives of formula (I) and their use as a drug, particularly for the treatment of cancer, are disclosed. Also disclosed are pharmaceutical compositions comprising the piperazinyl derivatives, and methods for synthesizing the piperazinyl derivatives.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 18, 2016
    Inventors: Denis CARNIATO, Jean-Francois BRIAND, Mathieu GUTMANN, Olivier BUSNEL, Cécile BOUGERET, Benoit DEPREZ, Karine JAILLARDON
  • Publication number: 20150307450
    Abstract: The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
    Type: Application
    Filed: December 6, 2013
    Publication date: October 29, 2015
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, BIOKINESIS
    Inventors: Cécile Bougeret, Catherine Guillou, Julien Rouleau, Julie Rivollier, Denis Carniato
  • Patent number: 8673955
    Abstract: Imidazole derivatives of formula (I): wherein R1, R2a, R2b, A, V and W are as defined in the description, as inhibitors of fructose-1,6-bisphosphatase, their preparation process and their use in the prevention or treatment of diabetes, and other diseases where the inhibition of gluconeogenesis, control of blood glucose levels, reduction in glycogen stores, or reduction in insulin levels is beneficial and diseases related to the insulin resistance syndrome.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: March 18, 2014
    Assignee: Merck Patent GmbH
    Inventors: Denis Carniato, Gérard Moinet, Gérard Botton, Annick Arbellot De Vacqueur, Annick Audet
  • Patent number: 8586577
    Abstract: The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: November 19, 2013
    Assignee: Merck Patent GmbH
    Inventors: Denis Carniato, Caroline Leriche, Didier Roche, Christine Charon, Liliane Doare
  • Patent number: 8546575
    Abstract: The present invention relates to NIP thiazole derivatives of formula (I) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: October 1, 2013
    Assignee: Merck Patent GmbH
    Inventors: Caroline Leriche, Denis Carniato, Didier Roche, Christine Charon, Liliane Doare
  • Patent number: 8519188
    Abstract: The present invention relates to a compound of general formula (I): and also to the pharmaceutically acceptable salts thereof, to the isomers or isomer mixtures thereof in all proportions, in particular to an enantiomer mixture, and especially to a racemic mixture. The present invention also relates to the use of these compounds as a medicament, and in particular for the treatment of cancer, and also to the compositions containing them.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: August 27, 2013
    Assignee: Marc-Henry Pitty
    Inventors: Denis Carniato, Karine Jaillardon, Olivier Busnel, Mathieu Gutmann, Jean-Francois Briand, Benoit Deprez, Dominique Thomas, Cécile Bougeret
  • Patent number: 8486964
    Abstract: The present invention relates to fused pyrrolidino-cyclopropane derivatives according to formulae (I) to (IV) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-?-HSD-1) and the use of such compounds for the treatment and/or prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: July 16, 2013
    Assignee: Merck Patent GmbH
    Inventors: Eric Valeur, Franck Lepifre, Didier Roche, Denis Carniato, Serge Christmann-Franck, Fabien Schmidlin
  • Patent number: 8470849
    Abstract: The present invention relates to 7-azaindole derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: June 25, 2013
    Assignee: Merck Patent GmbH
    Inventors: Denis Carniato, Didier Roche, Sophie Hallakou-Bozec, Melanie Schultz
  • Patent number: 8466200
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: June 18, 2013
    Assignee: Merck Patent GmbH
    Inventors: Denis Carniato, Christine Charon, Johannes Gleitz, Didier Roche, Bjoern Hock
  • Publication number: 20120283247
    Abstract: The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: July 17, 2012
    Publication date: November 8, 2012
    Applicant: MERCK PATENT GMBH
    Inventors: Denis CARNIATO, Caroline LERICHE, Didier ROCHE, Christine CHARON, Liliane DOARE
  • Patent number: 8242107
    Abstract: The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: August 14, 2012
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Denis Carniato, Caroline Leriche, Didier Roche, Christine Charon, Liliane Doare
  • Patent number: 8236824
    Abstract: Novel heterocyclic compounds of the formula I in which R1, R2, R3, R4, R5, R6, R7, Alk and D have the meanings indicated in claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: August 7, 2012
    Assignee: Merck Patent Gesellschaft mit Beschränkter Haftung
    Inventors: Lars Thore Burgdorf, Norbert Beier, Johannes Gleitz, Ulrich Emde, Christine Charon, Denis Carniato
  • Publication number: 20120172396
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: February 7, 2012
    Publication date: July 5, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Denis CARNIATO, Christine CHARON, Johannes GLEITZ, Didier ROCHE, Bjoern HOCK